Daniel Judge, MD, discussed late-breaking data on acoramidis, a new drug therapy for transthyretin amyloid cardiomyopathy. A final decision from the FDA on acoramidis is expected in the days ahead.

SCAI celebrated cardiologists William W. O'Neill, MD, and Cindy L. Grines, MD, for the important roles they played in the development of primary PCI. “It was challenging,” Grines explained. “We had the pharmaceutical industry that was anti-primary angioplasty and we had a lot of our own colleagues that were anti-primary angioplasty."

Self-expanding and balloon-expandable TAVR valves are associated with comparable success rates and one-year outcomes when treating type 1 bicuspid aortic stenosis. However, each valve type comes with its own advantages and disadvantages.

PCI can be more challenging in high-risk patients presenting with diabetes and ACS. IVUS guidance was associated with improved outcomes among these patients compared to angiography guidance alone. 

Martha Gulati, MD, spoke to Cardiovascular Business at AHA Scientific Sessions 2024 about key developments in obesity treatment and CVD prevention.